CTICライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (24 6月 2023 @ 04:58):

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States...

Stats
本日の出来高	5.56M
平均出来高	5.66M
時価総額	1.20B
EPS	$0 ( 2024-03-04 )
次の収益日	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.84
ATR14	$0.183 (2.01%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-26	Bvf Partners L P/il	Sell	43 139	Common Stock, par value $0.001
2023-06-26	Bvf Partners L P/il	Sell	12	Series X Convertible Preferred Stock
2023-06-26	Bvf Partners L P/il	Sell	17	Series X1 Convertible Preferred Stock
2023-06-26	Bvf Partners L P/il	Sell	120 000	Stock Option (Right to Buy)
2023-06-26	Bvf Partners L P/il	Sell	60 000	Stock Option (Right to Buy)

INSIDER POWER
-81.63
Last 99 transactions
Buy: 2 253 317 \| Sell: 15 023 868

ボリューム相関

長: 0.20 (neutral)

短: -0.41 (neutral)

Signal:(83.616) Neutral

CTI Biopharma Corp 相関

10 最も正の相関
APYX	0.961
DRNA	0.957
DMRC	0.956
EVLV	0.956
IZEA	0.952
BOXL	0.95
CELH	0.947
GT	0.944
GSMG	0.943
ALBO	0.942

10 最も負の相関
ITI	-0.951
MBIN	-0.937
VRCA	-0.928
CPRX	-0.928
AMPH	-0.922
INOD	-0.922
SPPI	-0.921
NVCT	-0.914
SLMBP	-0.914
PMTS	-0.913

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

CTI Biopharma Corp 相関 - 通貨/商品

0.25
( neutral )

0.69
( moderate )

0.57
( weak )

0.52
( weak )

-0.27
( neutral )

-0.29
( neutral )

CTI Biopharma Corp 財務諸表

Annual	2022
収益:	$53.95M
総利益:	$50.43M (93.49 %)
EPS:	$-0.790

FY	2022
収益:	$53.95M
総利益:	$50.43M (93.49 %)
EPS:	$-0.790

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.090

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.740

Financial Reports:

No articles found.

CTI Biopharma Corp

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.